Recent studies in photopharmacology focus on developing switchable beta blockers that can be activated or deactivated by specific wavelengths of light.
This innovative approach aims to improve the precision of medication delivery, allowing for targeted treatments that minimize adverse effects.
The implications for healthcare infrastructure are significant, as this technology could lead to more efficient drug administration protocols and better patient outcomes.